Status:
COMPLETED
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Lead Sponsor:
Savient Pharmaceuticals
Conditions:
Gout
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
These are two replicate studies to evaluate the safety and efficacy of PEG (polyethylene glycol)-uricase in controlling the uric acid level in symptomatic gout patients with high uric acid levels who ...
Detailed Description
The primary objective of each of the studies is to demonstrate superiority in the response rate (control of uric acid levels to below 6 mg/dL) in the PEG-uricase treatment groups compared to the place...
Eligibility Criteria
Inclusion
- Outpatients of either gender, age 18 or older ( no upper age limit).
- Patient is hyperuricemic: screening serum uric acid must be ≥8 mg/dL.
- Patient has symptomatic gout (presence of at least 3 gout flares in the 18 months prior to entry, or at least one gout tophus, or gouty arthritis).
- Conventional therapy is contraindicated or has been ineffective in this patient, i.e., patient has a history (either by medical record or patient interview) of hypersensitivity or of failure to normalize SUA with at least 3 months treatment with allopurinol at the maximum labeled dose (800 mg/dL in the U.S.), or at a medically appropriate lower dose based on dose-limiting toxicity or dose-limiting co-morbidity.
- Patient is willing and able to give informed consent and adhere to visit/protocol schedules (informed consent must be given before the first study procedure is performed, including washout).
- If the patient is a woman of childbearing potential, she must have had a negative screening serum pregnancy test and must use a medically approved form of birth control during her participation in the protocol. Such methods include oral, injectable or implantable contraceptives; IUDs and barrier contraceptives in combination with spermicide. (If male or surgically sterile, check N/A.)
Exclusion
- The patient has unstable angina.
- The patient has uncontrolled arrhythmia.
- The patient has non-compensated congestive heart failure.
- The patient has uncontrolled hypertension (above 150/95).
- The patient has a history of end stage renal disease requiring dialysis.
- The patient has hemoglobin \< 8 g/dL (males) or \< 7 g/dL (females).
- The patient is an organ transplant recipient
- The patient has had prior treatment with PEG-uricase, or other recombinant uricase, or any concomitant therapy with a PEG-conjugated drug.
- The patient has had a gout flare at screening that is resolved for less than one week prior to first treatment with study drug (exclusive of chronic synovitis/ arthritis).
- The patient has glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- The patient has a history of anaphylactic reaction to a recombinant protein or porcine product, or hypersensitivity to PEG.
- The patient is pregnant or breast feeding.
- The patient has taken an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study.
- The patient has a known allergy to urate oxidase or PEGylated products.
- The patient has any other medical or psychological condition which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
225 Patients enrolled
Trial Details
Trial ID
NCT00325195
Start Date
May 1 2006
End Date
December 1 2007
Last Update
February 28 2011
Active Locations (56)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB Arthritis Clinical Intervention Program
Birmingham, Alabama, United States, 35294
2
University of Arizona Arthritis Center
Tucson, Arizona, United States, 85724
3
NEA Clinic
Jonesboro, Arkansas, United States, 72401
4
UCSD Rheumatology Division
La Jolla, California, United States, 92037-0943